+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Infertility Drugs Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034)

  • PDF Icon

    Report

  • 400 Pages
  • June 2025
  • Region: Global
  • Expert Market Research
  • ID: 5805789
The infertility drugs market attained a value of USD 3.70 Billion in 2024 driven by the rising cases of infertility among men and women across the 8 major markets. It is expected to grow at a CAGR of 5.90% in the forecast period of 2025-2034 and attain a market value of USD 6.56 Billion by 2034.

Infertility Drugs Market Overview

Infertility drugs help in managing and treating infertility issues in both males and females. It can help in stimulating ovulation in women and balancing hormone levels necessary for reproductive health. In males, it may increase sperm count. Clomiphene citrate gonadotropins aromatase inhibitors are amongst the most frequently used medications that help infertility.

Infertility Drugs Market Growth Drivers

Rising Cases of Infertility among Men and Women to Boost the Growth of the Industry

According to the World Health Organisation's 2023 report, 1 in 6 people across the world are expected to witness difficulties conceiving, highlighting the dire requirement of accessible yet quality fertility care. The rising prevalence of infertility-related diseases such as hormonal imbalances, endometriosis, and ovarian cysts is a key factor driving the demand for infertility drugs. In addition, fertility issues are further worsened by stress, obesity, and smoking.

Infertility Drugs Market Trends

Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:

Rise in Partnerships Between Key Market Players

In June 2024, Ferring Pharmaceuticals collaborated with Posterity Health to introduce a Male Fertility program on the Fertility Out Loud platform. This program provides an online evaluation to assist men in comprehending their fertility condition with private surveys and educational materials developed by reproductive urologists. The goal of the program is to reduce the stigma related to male infertility, prompt early assessment, and support fair fertility procedures for couples, ultimately creating a more inclusive and efficient fertility experience.

Growing Popularity of Personalized Fertility Treatments

Fertility treatments now rely more on personalized medicine practice with patient-specific drug regimens determined by an individual's genetic, hormonal, and health characteristics. It is intended to enhance the effectiveness and reduce side effects from the treatment.

Adoption of Telemedicine to Meet the Rising Infertility Drugs Market Demand

The use of online consultations in medicine is becoming popular, providing greater access to patients located far from physical clinics. Fertility experts can also diagnose and treat patients from a distance using telemedicine services, providing increased convenience and the possibility of reduced costs for treatment.

Increasing Demand for Non-Invasive and Minimally Invasive Treatment Options

Fewer patients are willing to risk higher invasive fertility treatments. This need is making pharmaceutical companies invent oral and injectable forms of the drugs providing safe results with fewer procedural hazards.

Infertility Drugs Market Segmentation

“Infertility Drugs Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:

Market Breakup by Drug Class

  • Gonadotrophins
  • Aromatase Inhibitors
  • Selective Estrogen Receptor Modulators (SERMs)
  • Biguanides
  • Others

Market Breakup by Gender

  • Male
  • Female

Market Breakup by Route of Administration

  • Oral
  • Injectable

Market Breakup by Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Market Breakup by Region

  • United States
  • EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India

Infertility Drugs Market Share

The Gonadotrophins Segment Based on Drug Class Holds a Significant Share in the Market

The market is segmented by drug class into gonadotrophins, aromatase inhibitors, selective estrogen receptor modulators (SERMs), biguanides, and others. The gonadotrophins drug class is anticipated to be the dominant segment among these. The market share can be attributed to its ability to considerably increase pregnancy chances in women. Women are also learning more about the decreased side effects of gonadotrophins, which boosts the market value of this segment.

Market Segmentation Based on Gender

Based on gender, the market is segmented into male and female. Among these, the female segment is expected to lead the market, as a large range of drugs is available for addressing female infertility issues. These drugs may involve ovulation stimulators, hormone treatments, and follicle-stimulating agents. In assisted reproductive technology (ART) procedures, such as in vitro fertilization (IVF), medications are more common for female patients.

Infertility Drugs Market Analysis by Region

The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan, and India. Among these, the United States is expected to dominate the market due to its high disease prevalence rates and funding for research. Such areas are underpinned by the aging population and lifestyle-related risks in market growth. Support from the government and healthcare systems driving market expansion as it leads in clinical trials is a pioneer in treating the disease with targeted therapies, and immunotherapies. Rising emphasis on early diagnosis and customized treatment options is driving the market.

Leading Players in the Infertility Drugs Market

The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:

Mankind Pharma

Established in New Delhi in 1991, Mankind Pharma is one of India's top-notch pharmaceutical companies. Its product range includes Siphene (clomphene citrate) which is an ovulation inducer widely used for female infertility. The fertility market in India as everywhere else is ever-growing and Mankind Pharma with its vision of treatment made affordable, ensures access to the widest range for the widest population.

Pfizer Inc

Pfizer, which was established in 1849 and has its headquarters in New York City is a leading global pharmaceutical company as well. Menopur (menotropins) is a common drug in the company portfolio and is used to induce ovulation in women undergoing fertility treatment in the infertility drugs market.

Novartis AG

Novartis is headquartered in Basel, Switzerland, and was founded in 1996 as a pharmaceutical company specializing in specialty and generics. Infertility treatments from Novartis include hormone-based therapies to assist in ART procedures. The company provides a variety of patient solutions by delivering progressive infertility drugs around the world and creating patient-friendly approaches for use with fertility treatment.

Bayer AG

Bayer was founded in 1863 and is based in Leverkusen, Germany. It is best known for Puregon (follitropin beta), which is an artificial regimen that produces ovulation induction. Bayer's stronghold in hormone therapies is a leading combatant in the market and has already been conducting rigorous research aimed at developing cutting-edge solutions for female infertility as well as male infertility.

Other companies include Merck KGaA, Ferring Pharmaceuticals Inc., Thermo Fisher Scientific, Inc., THERAMEX HQ UK LIMITED, Teva Pharmaceuticals Industries Ltd, and Livzon Pharmaceutical Group Inc., among others.

Key Questions Answered in the Infertility Drugs Market

  • What was the infertility drugs market value in 2023?
  • What is the infertility drugs market forecast outlook for 2024- 2032?
  • What are the regional markets covered in the report?
  • What is the market segmentation based on the drug class?
  • What is the market segmentation based on the gender?
  • What is the market breakup by route of administration?
  • What is the market breakup based on the distribution channel?
  • What major factors aid the infertility drugs market demand?
  • What are the market's major drivers, opportunities, and restraints?
  • Which regional market is expected to lead the market share in the forecast period?
  • Which country is expected to experience expedited growth during the forecast period?
  • What are the major infertility drugs market trends?
  • How does the rise in the geriatric population impact the market size?
  • Who are the key players in the infertility drugs market?
  • What are the current unmet needs and challenges in the market?
  • How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
  • Why are gonadotrophins widely used in infertility treatments?
  • Which infertility drugs are specifically targeted for male patients?
  • What are the benefits of oral infertility drugs?
  • What role do hospital pharmacies play in infertility treatment distribution?
  • Why is the United States a leading market for infertility drugs?
  • How is India’s growing healthcare infrastructure impacting infertility drug demand?

This product will be delivered within 3-5 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Infertility Drugs Market Overview: 8 Major Market
3.1 Infertility Drugs Market Historical Value (2018-2024)
3.2 Infertility Drugs Market Forecast Value (2025-2034)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Infertility: Disease Overview
5.1 Guidelines and Stages
5.2 Pathophysiology
5.3 Screening and Diagnosis
5.4 Therapy Pathway
6 Patient Profile
6.1 Patient Profile Overview
6.2 Patient Psychology and Emotional Impact Factors
6.3 Risk Assessment and Therapy Success Rate
7 Infertility Drugs Market Epidemiology Scenario and Forecast - 8 Major Markets
7.1 8MM Epidemiology Scenario Overview (2018-2034)
7.1.1 Prevalence, by Country
7.1.1.1 U.S.
7.1.1.2 U.K.
7.1.1.3 EU4
7.1.1.4 India
7.1.1.5 Japan
7.1.2 Mortality by Country
7.1.2.1 U.S.
7.1.2.2 U.K.
7.1.2.3 EU4
7.1.2.4 India
7.1.2.5 Japan
7.1.3 Treatment Seeking Rate by Country
7.1.3.1 U.S.
7.1.3.2 U.K.
7.1.3.3 EU4
7.1.3.4 India
7.1.3.5 Japan
8 Infertility Drugs Market Landscape: 8 Major Market*
8.1 Infertility Drugs Market: Developers Landscape
8.1.1 Analysis by Year of Establishment
8.1.2 Analysis by Company Size
8.1.3 Analysis by Region
8.2 Infertility Drugs Market: Product Landscape
8.2.1 Analysis by Drug Class
8.2.2 Analysis by Gender
8.2.3 Analysis by Route of Administration
9 Infertility Drugs Market Challenges and Unmet Needs
9.1 Therapy Pathway Challenges
9.2 Compliance and Drop-Out Analysis
9.3 Awareness and Prevention Gaps
10 Cost of Therapy
11 Infertility Drugs Market: Market Dynamics
11.1 Market Drivers and Constraints
11.2 SWOT Analysis
11.2.1 Strengths
11.2.2 Weaknesses
11.2.3 Opportunities
11.2.4 Threats
11.3 PESTEL Analysis
11.3.1 Political
11.3.2 Economic
11.3.3 Social
11.3.4 Technological
11.3.5 Legal
11.3.6 Environment
11.4 Porter’s Five Forces Model
11.4.1 Bargaining Power of Suppliers
11.4.2 Bargaining Power of Buyers
11.4.3 Threat of New Entrants
11.4.4 Threat of Substitutes
11.4.5 Degree of Rivalry
11.5 Key Demand Indicators
11.6 Key Price Indicators
11.7 Industry Events, Initiatives, and Trends
11.8 Value Chain Analysis
12 Infertility Drugs Market Segmentation: 8 Major Markets
12.1 Infertility Drugs Market (2018-2034) by Drug Class
12.1.1 Market Overview
12.1.2 Gonadotrophins
12.1.3 Aromatase Inhibitors
12.1.4 Selective Estrogen Receptor Modulators (SERMs)
12.1.5 Biguanides
12.1.6 Others
12.2 Infertility Drugs Market (2018-2034) by Gender
12.2.1 Market Overview
12.2.2 Male
12.2.3 Female
12.3 Infertility Drugs Market (2018-2034) by Route of Administration
12.3.1 Market Overview
12.3.2 Oral
12.3.3 Injectable
12.4 Infertility Drugs Market (2018-2034) by Distribution Channel
12.4.1 Market Overview
12.4.2 Hospital Pharmacy
12.4.3 Online Pharmacy
12.4.4 Retail Pharmacy
12.5 Infertility Drugs Market (2018-2034) by Region
12.5.1 Market Overview
12.5.2 United States
12.5.3 EU-4 and the United Kingdom
12.5.3.1 Germany
12.5.3.2 France
12.5.3.3 Italy
12.5.3.4 Spain
12.5.3.5 United Kingdom
12.5.4 Japan
12.5.5 India
13 United States Infertility Drugs Market (218-2034)
13.1 United States Infertility Drugs Market Historical Value (2018-2024)
13.2 United States Infertility Drugs Market Forecast Value (2025-2034)
13.3 United States Infertility Drugs Market (2018-2034) by Drug Class
13.3.1 Market Overview
13.3.2 Gonadotrophins
13.3.3 Aromatase Inhibitors
13.3.4 Selective Estrogen Receptor Modulators (SERMs)
13.3.5 Biguanides
13.3.6 Others
13.4 United States Infertility Drugs Market (2018-2034) by Gender
13.4.1 Market Overview
13.4.2 Male
13.4.3 Female
13.5 United States Infertility Drugs Market (2018-2034) by Route of Administration
13.5.1 Market Overview
13.5.2 Oral
13.5.3 Injectable
13.6 United States Infertility Drugs Market (2018-2034) by Distribution Channel
13.6.1 Market Overview
13.6.2 Hospital Pharmacy
13.6.3 Online Pharmacy
13.6.4 Retail Pharmacy
14 Retail PharmacyEU-4 and United Kingdom Infertility Drugs Market (218-2034)
14.1 EU-4 and United Kingdom Infertility Drugs Market Historical Value (2018-2024)
14.2 EU-4 and United Kingdom Infertility Drugs Market Forecast Value (2025-2034)
14.3 EU-4 and United Kingdom Infertility Drugs Market (2018-2034) by Drug Class
14.3.1 Market Overview
14.3.2 Gonadotrophins
14.3.3 Aromatase Inhibitors
14.3.4 Selective Estrogen Receptor Modulators (SERMs)
14.3.5 Biguanides
14.3.6 Others
14.4 EU-4 and United Kingdom Infertility Drugs Market (2018-2034) by Gender
14.4.1 Market Overview
14.4.2 Male
14.4.3 Female
14.5 EU-4 and United Kingdom Infertility Drugs Market (2018-2034) by Route of Administration
14.5.1 Market Overview
14.5.2 Oral
14.5.3 Injectable
14.6 EU-4 and United Kingdom Infertility Drugs Market (2018-2034) by Distribution Channel
14.6.1 Market Overview
14.6.2 Hospital Pharmacy
14.6.3 Online Pharmacy
14.6.4 Retail Pharmacy
15 Japan Infertility Drugs Market
15.1 Japan Infertility Drugs Market Historical Value (2018-2024)
15.2 Japan Infertility Drugs Market Forecast Value (2025-2034)
15.3 Japan Infertility Drugs Market (2018-2034) by Drug Class
15.3.1 Market Overview
15.3.2 Gonadotrophins
15.3.3 Aromatase Inhibitors
15.3.4 Selective Estrogen Receptor Modulators (SERMs)
15.3.5 Biguanides
15.3.6 Others
15.4 Japan Infertility Drugs Market (2018-2034) by Gender
15.4.1 Market Overview
15.4.2 Male
15.4.3 Female
15.5 Japan Infertility Drugs Market (2018-2034) by Route of Administration
15.5.1 Market Overview
15.5.2 Oral
15.5.3 Injectable
15.6 Japan Infertility Drugs Market (2018-2034) by Distribution Channel
15.6.1 Market Overview
15.6.2 Hospital Pharmacy
15.6.3 Online Pharmacy
15.6.4 Retail Pharmacy
16 India Infertility Drugs Market
16.1 India Infertility Drugs Market Historical Value (2018-2024)
16.2 India Infertility Drugs Market Forecast Value (2025-2034)
16.3 India Infertility Drugs Market (2018-2034) by Drug Class
16.3.1 Market Overview
16.3.2 Gonadotrophins
16.3.3 Aromatase Inhibitors
16.3.4 Selective Estrogen Receptor Modulators (SERMs)
16.3.5 Biguanides
16.3.6 Others
16.4 India Infertility Drugs Market (2018-2034) by Gender
16.4.1 Market Overview
16.4.2 Male
16.4.3 Female
16.5 India Infertility Drugs Market (2018-2034) by Route of Administration
16.5.1 Market Overview
16.5.2 Oral
16.5.3 Injectable
16.6 India Infertility Drugs Market (2018-2034) by Distribution Channel
16.6.1 Market Overview
16.6.2 Hospital Pharmacy
16.6.3 Online Pharmacy
16.6.4 Retail Pharmacy
17 Regulatory Framework
17.1 Regulatory Overview
17.2 US FDA
17.3 EU EMA
17.4 INDIA CDSCO
17.5 JAPAN PMDA
17.6 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication Year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Clinical Trial Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Grant Analysis
20.1 Analysis by Year
20.2 Analysis by Amount Awarded
20.3 Analysis by Issuing Authority
20.4 Analysis by Grant Product
20.5 Analysis by Funding Institute
20.6 Analysis by Departments
20.7 Analysis by Recipient Organization
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Strategic Initiatives
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Market Share by Top 5 Companies
23.2 Merck KGaA
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Company News and Developments
23.2.5 Certifications
23.3 Mankind Pharma
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Company News and Developments
23.3.5 Certifications
23.4 Pfizer Inc.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Company News and Developments
23.4.5 Certifications
23.5 Ferring Pharmaceuticals Inc.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Company News and Developments
23.5.5 Certifications
23.6 Thermo Fisher Scientific, Inc.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Company News and Developments
23.6.5 Certifications
23.7 Novartis AG
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Company News and Developments
23.7.5 Certifications
23.8 Bayer AG
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Company News and Developments
23.8.5 Certifications
23.9 THERAMEX HQ UK LIMITED
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Company News and Developments
23.9.5 Certifications
23.10 Teva Pharmaceticals Industries Ltd.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Company News and Developments
23.10.5 Certifications
23.11 Livzon Pharmaceutical Group Inc
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Company News and Developments
23.11.5 Certifications
24 Infertility Drugs Market - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket

Companies Mentioned

  • Mankind Pharma
  • Pfizer Inc.
  • Novartis AG
  • Bayer AG

Table Information